A Nationwide Danish Comparative Effectiveness Study of GLP‐1 RA, SGLT2i and DPP‐4i Treatment on Risk of Stroke, Myocardial Infarction and Mortality in Type 2 Diabetes
ABSTRACT Aims Cardiovascular outcome trials have demonstrated that glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of major adverse cardiovascular events, whereas dipeptidyl peptidase‐4 inhibitors (DPP‐4i) have not shown car...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Wiley
2026-01-01
|
| Series: | Endocrinology, Diabetes & Metabolism |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1002/edm2.70165 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|